Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer

A comprehensive review of current data

Petros Charalampoudis, Christos Markopoulos, T. Kovács

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

In primary breast cancer, sentinel lymph node biopsy has been established as the gold standard for regional axillary staging. A robust body of randomized data support its accuracy and safety in patients with early, clinically node negative disease. However, the role of SLNB remains debatable in various patient subgroups, and recent advances in histopathology, dedicated axillary ultrasound imaging and chemotherapy regimens, put its role under a new perspective. Herein, we review the current literature data on the indications for SLNB and discuss the challenges in management germane to special patient subgroups and patterns of disease. We also present emerging data on the optimal management of the SLN+ patient, in light of recent trials challenging the dogma of completion axillary dissection after a positive sentinel node biopsy.

Original languageEnglish
Pages (from-to)5-14
Number of pages10
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Patient Safety
Dissection
Ultrasonography
Biopsy
Drug Therapy

Keywords

  • Axillary ultrasound
  • Breast cancer
  • Neoadjuvant chemotherapy
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer : A comprehensive review of current data. / Charalampoudis, Petros; Markopoulos, Christos; Kovács, T.

In: European Journal of Surgical Oncology, Vol. 44, No. 1, 01.01.2018, p. 5-14.

Research output: Contribution to journalReview article

@article{7baecf0301fc44f8960ad0d0e6ebff9f,
title = "Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: A comprehensive review of current data",
abstract = "In primary breast cancer, sentinel lymph node biopsy has been established as the gold standard for regional axillary staging. A robust body of randomized data support its accuracy and safety in patients with early, clinically node negative disease. However, the role of SLNB remains debatable in various patient subgroups, and recent advances in histopathology, dedicated axillary ultrasound imaging and chemotherapy regimens, put its role under a new perspective. Herein, we review the current literature data on the indications for SLNB and discuss the challenges in management germane to special patient subgroups and patterns of disease. We also present emerging data on the optimal management of the SLN+ patient, in light of recent trials challenging the dogma of completion axillary dissection after a positive sentinel node biopsy.",
keywords = "Axillary ultrasound, Breast cancer, Neoadjuvant chemotherapy, Sentinel lymph node biopsy",
author = "Petros Charalampoudis and Christos Markopoulos and T. Kov{\'a}cs",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ejso.2017.10.215",
language = "English",
volume = "44",
pages = "5--14",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer

T2 - A comprehensive review of current data

AU - Charalampoudis, Petros

AU - Markopoulos, Christos

AU - Kovács, T.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In primary breast cancer, sentinel lymph node biopsy has been established as the gold standard for regional axillary staging. A robust body of randomized data support its accuracy and safety in patients with early, clinically node negative disease. However, the role of SLNB remains debatable in various patient subgroups, and recent advances in histopathology, dedicated axillary ultrasound imaging and chemotherapy regimens, put its role under a new perspective. Herein, we review the current literature data on the indications for SLNB and discuss the challenges in management germane to special patient subgroups and patterns of disease. We also present emerging data on the optimal management of the SLN+ patient, in light of recent trials challenging the dogma of completion axillary dissection after a positive sentinel node biopsy.

AB - In primary breast cancer, sentinel lymph node biopsy has been established as the gold standard for regional axillary staging. A robust body of randomized data support its accuracy and safety in patients with early, clinically node negative disease. However, the role of SLNB remains debatable in various patient subgroups, and recent advances in histopathology, dedicated axillary ultrasound imaging and chemotherapy regimens, put its role under a new perspective. Herein, we review the current literature data on the indications for SLNB and discuss the challenges in management germane to special patient subgroups and patterns of disease. We also present emerging data on the optimal management of the SLN+ patient, in light of recent trials challenging the dogma of completion axillary dissection after a positive sentinel node biopsy.

KW - Axillary ultrasound

KW - Breast cancer

KW - Neoadjuvant chemotherapy

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=85034979108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034979108&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2017.10.215

DO - 10.1016/j.ejso.2017.10.215

M3 - Review article

VL - 44

SP - 5

EP - 14

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -